213 results about "Urokinase" patented technology

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

The invention provides a fusion protein formed by the combination of urokinase-type plasminogen activator a chain and melittin, the preparation method thereof, and the application of the fusion protein in tumor treatment.

The invention is about a method to purify the recombined human urokinase by the chromatography. The invention relates to recovery the gene engineering production from the mammal cell culture using the Streamline-SP, Sephacryl S-200, Sepharose Fast Flow and DEAE-Sepharose Fast Flow method. The recombined human urokinase can meet the SFDA standard and the percent recovery is above 70%, the purity is above 99% by using the method.

The invention relates to a urine protein enriching method. In the method, urine protein in urine is absorbed directly by an adsorbent in a urinal or a pee hopper, and the adsorbent for adsorbing the urine protein is conveyed to a working point for follow-up treatment; and based on the isoelectric point properties of specific urine protein, the urine protein such as urinary trypsin inhibitor, human urinary kininogenase, urokinase and the like is adsorbed directly and effectively by using the specific adsorbent such as ion exchange resin, and thus, the step of collecting the urine is avoided. The method does not influence sanitation of toilets obviously, reduces the cost of urine transportation substantially and solves a series of environmental problems.

The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.

The invention relates to a tumor-targeted hollow core-shell structure nano diagnosis-treatment agent and a preparation method thereof. The nano diagnosis-treatment agent comprises an upconversion nanoparticle inner core, an organic-inorganic hybrid silica shell layer and an intermediate cavity structure, can improve the load capacity of a photosensitizer and reduce the photosensitizer aggregation, and can specifically recognize cancer cells by connecting tumor-targeted molecules (such as urokinase ammonia terminal fragments) to the surface; under the irradiation of 980 nm laser, a visible light emission sensitizing photosensitizer of the nano diagnosis-treatment agent generates singlet oxygen, so that the photodynamic therapy of cancer cells can be performed; in addition, the nano diagnosis-treatment agent can be used for the upconversion luminescence and CT dual-mode imaging by utilizing the upconversion luminescence and strong X-ray absorption characteristics.

The invneiton relates to expression, purification and crystallization of urokinase catalytic domain mutant, relating to the field of medicine, biotechnique, and structural biology. And the invention provides a techical method of expression, purification and crystallization of urokinase catalytic domain mutant in Pichia pastoris. And the cultured urokinase catalytic domain mutant has crystallographic space group R3, and unit cell parameters: a=b=120.48, c=42.45, alpha=beta=90.0deg, and gama=120.0 deg. And this protein has serine proteinase activity, appliable to high flux screening of urokinase inhibitor; and its high resolution crystal provides a research and development platform for design and development of urokinase inhibitor.

The invention relates to a separation purification method of urokinase. The separation purification method is characterized by comprising the following steps: (1) separating the urokinase; and (2) purifying the urokinase. The preparation method specifically comprises the following steps: (a) collecting urine of men, adjusting the pH value of the urine to 8.5 at the temperature of 10 DEG C or lower, standing for 2h, and removing precipitates, thus obtaining supernatant; (b) taking the supernatant, adjusting the pH to 5.0 to 5.5, acidifying to obtain acidified urine, and adsorbing the acidified urine by virtue of a diatomite column; (c) washing the diatomite column by cold water of 5 DEG C, eluting by utilizing 1% ammonia water and sodium chloride to obtain an elution solution; (d) salting out the elution solution by utilizing saturated ammonium sulfate and 4% ammonia water to obtain a urokinase crude product; and (e) adding a given amount of ammonia water into the precipitates, sufficiently dissociating the urokinase in the precipitates to obtain a urokinase solution.

A novel natto bacillus subtilis BSNK-T160 is obtained through irradiation mutagenesis. Compared with the wild fungus BSNK-5, the casein hydrolytic activity of the BSNK-T160 is improved by 46.9% and the thermal stability at a temperature of 65 DEG C is improved by eight times; the fibrin activity is improved by 29.62% and the thermal stability is improved by 82.31% compared with a urokinase. The strain BSNK-T160 can be used for producing the nattokinase with the high activity and thermal stability. The nattoes with superior quality can be produced through fermentation of soybeans for 24h by using the stain.

A specific purified high-molecular urokinase chromatography media is characterized by having a structure as follows: HOOC-(CH2)4(NH)C-O-R-O-C(NH)NH(CH2)4-CO-X,X=NHC6H5C(NH)NH2, wherein R represents cross-linked agarose substrate. The specific purified high-molecular urokinase chromatography media has the advantages of being simple in preparation process and mild for reaction conditions, being applicable to high-efficiency separation of high-molecular urokinase media and low-molecular urokinase media, and being capable of implementing industrial production of high-purification and high-molecular urokinase.

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

A thrombus target fusion mA5UKB with both anticoagulating and thrombolytic functions is prepared from the mutant mAnxA5 of AnnexinA5 having anti-coagulating function and the urokinase B chain (UKB) having thrombolytic function through fusing. It can be used to prepare the thrombolytic medicine.

A polypeptide presenting an epitope cross-reactive with an epitope of urokinase-type plasminogen activator receptor, and/or having uPA binding activity, is described.

The invention relates to a urinary protein enriching method which comprises the steps of directly adsorbing urinary proteins in urine in urinals or urinating buckets with filter cloth bags loaded with modified silica gel, and transporting the urinary protein adsorbed filter cloth bags to working points for subsequent treatment. According to the method, the isoelectric point property of specific urinary proteins is utilized, and urinary proteins such as urinary trypsin inhibitors, human urinary kininogenase, urokinase and the like are effectively absorbed directly by using the modified silica gel, macroporous resin, chitin, ionic resin and the like, so that a urine collecting step is avoided. The method is free of obvious influence on sanitary conditions of toilets, and the cost for urine transportation and a series of environmental problems resulting from urine transportation are greatly reduced.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.